Association of plasma BDNF and MMP-9 levels with mild cognitive impairment: a matched case-control study DOI Creative Commons
Tingyu Zhang, Hang Si,

Jiali Liao

и другие.

Scientific Reports, Год журнала: 2024, Номер 14(1)

Опубликована: Дек. 28, 2024

The prevalence of Alzheimer's disease (AD) is on the rise globally, and everyone who develops AD eventually experiences mild cognitive impairment (MCI) first. Timely intervention at an early stage may mitigate progression. Recent studies indicate that BDNF MMP-9 play a significant role in pathogenesis AD. Therefore, this study aims to ascertain whether there are differences plasma levels between individuals with due those normal cognition, analyze factors influencing impairment.This case-control included 102 controls, matched by age sex. Participants completed series questionnaires, neuropsychological assessments, clinical examinations. Plasma concentrations participants were quantified using ELISA. Subsequently, MCI analyzed univariate multivariate logistic regression. levels, MOCA total scores, scores various domains (including visuospatial executive abilities, abstract thinking, attention, language, naming, delayed memory) control groups showed statistically (p < 0.05). Logistic regression analysis revealed years formal education significantly negatively associated MCI. This indicates protective function.

Язык: Английский

The two cut‐offs approach for plasma p‐tau217 in detecting Alzheimer's disease in subjective cognitive decline and mild cognitive impairment DOI Creative Commons
Giulia Giacomucci,

Chiara Crucitti,

Assunta Ingannato

и другие.

Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring, Год журнала: 2025, Номер 17(2)

Опубликована: Апрель 1, 2025

Abstract BACKGROUND The study aimed to explore the applicability of plasma phosphorylated tau (p‐tau)217 in identifying patients with subjective cognitive decline (SCD) and mild impairment (MCI) carrying Alzheimer's disease (AD) pathology real‐world settings. METHODS Fifty SCD, 87 MCI, 50 AD‐demented underwent blood collection dose p‐tau217 a fully automated Lumipulse G600II assay. Patients were classified according Revised Criteria Association Workgroup as Core1+ or Core1– (based on amyloid positron emission tomography, cerebrospinal fluid [CSF] beta [Aβ]42/Aβ40, CSF p‐tau181/Aβ42). RESULTS Plasma was accurate for discriminating between (area under curve = 0.92) an optimal cut‐off value 0.274 pg/mL, revealing good accuracy (86.29%), positive predictive (PPV; 88.18%), negative (NPV; 83.09%). two cut‐offs approach (0.229–0.516 pg/mL) showed higher (91.11%), PPV 96.25% NPV 83.63%. CONCLUSION provides stronger accuracy, PPV, than single cut‐off, making reliable clinical application early detection AD Highlights highly detecting pathology. increased diagnosis. Even when measured immunoassay, is biomarker Transition from research setting practice seems feasible.

Язык: Английский

Процитировано

0
Advances in blood‐based phosphorylated tau protein biomarkers and their detection technology for Alzheimer's disease DOI Creative Commons

Shi-Yuan Fu,

Qiaoping Zheng,

Beihui Xu

и другие.

View, Год журнала: 2025, Номер unknown

Опубликована: Май 12, 2025

Abstract Alzheimer's disease (AD) is a prevalent neurodegenerative disorder characterized primarily by memory loss and impaired cognitive function. With the aging world population, incidence of AD rising, imposing substantial medical economic burdens on society. Current diagnostic methods for predominantly rely imaging studies cerebrospinal fluid analysis, which has limitations such as complex operation high costs. Therefore, development minimally invasive, convenient, accessible blood‐based biomarkers become research hotspot. Phosphorylated tau protein (p‐tau) plays crucial role in AD, its abnormal phosphorylation closely related to pathogenesis disease. This paper highlights potential applications three specific phosphorylated proteins—p‐tau217, p‐tau181, p‐tau231—in early diagnosis, differential progression monitoring aiming provide reference future clinical applications. Furthermore, reviews advancements various ultrasensitive detection technologies p‐tau measurement. The application these significantly enhanced sensitivity specificity detection, making it feasible detect low concentrations blood proteins, thereby advancing diagnosis AD.

Язык: Английский

Процитировано

0
Exploring the association between mild behavioral impairment and plasma p‐tau217: Implications for early detection of Alzheimer's disease DOI Creative Commons
Maryam Ghahremani,

Rebeca Leon,

Eric E. Smith

и другие.

Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring, Год журнала: 2025, Номер 17(2)

Опубликована: Апрель 1, 2025

Язык: Английский

Процитировано

0
Neuroimaging and plasma biomarker differences and commonalities in Lewy body dementia subtypes DOI Creative Commons
Naomi Hannaway, Angeliki Zarkali, Rohan Bhome

и другие.

Alzheimer s & Dementia, Год журнала: 2025, Номер 21(5)

Опубликована: Май 1, 2025

Abstract INTRODUCTION Despite ongoing debate about whether Parkinson's disease (PD) dementia (PDD) and with Lewy bodies (DLB) are separable diseases or a single body (LBD) spectrum, there limited investigations of differences between these conditions. METHODS We used fixel‐based diffusion magnetic resonance imaging plasma measures to examine white matter integrity burden amyloid pathology (using phosphorylated tau‐217 [p‐tau217]) in 47 patients DLB, 21 PDD, 29 PD, 23 age‐matched controls. RESULTS show reduced fiber cross‐section LBD versus increased concentrations neurofilament light chain p‐tau217; p‐tau217 associated cognition. Fiber density was PDD but neither nor differed subtypes. DISCUSSION Our findings suggest that the presence is poorer macrostructure may relate pathological protein accumulation. Conversely, DLB be driven by other factors. Highlights Plasma were relative Magnetic (MRI) (fiber cross‐section) PD. In contrast, MRI microstructure density) PD compared bodies. Differences distinct those normal differ underlying processes from driving dementia.

Язык: Английский

Процитировано

0
Diagnostic performance of plasma p-tau217 in a memory clinic cohort using the Lumipulse automated platform DOI Creative Commons
Francisco Martínez‐Dubarbie, Armando Ruiz, Sara López‐García

и другие.

Alzheimer s Research & Therapy, Год журнала: 2025, Номер 17(1)

Опубликована: Март 27, 2025

Plasma biomarkers for Alzheimer's disease (AD) are a promising tool accessible and accurate biological diagnostics. However, data in clinical practice needed to better understand their diagnostic prognostic ability memory unit patients. We analyzed plasma phosphorylated tau at threonine 217 (p-tau217) neuroflament light chain (NfL) levels AD cerebrospinal fluid (CSF) group of 493 subjects using the Lumipulse G600II platform. The sample includes 340 patients from our (142 dementia, 186 mild cognitive impairment, 12 with subjective complaints) 153 cognitively unimpaired volunteers. have correlated CSF biomarkers; we biomarker as function diagnosis, status amyloid status. also studied p-tau217 discriminate between amyloid-positive -negative according receiver operating characteristic curves. significantly Aβ42/Aβ40 (Rho = -0.75; p-value < 0.001), p-tau181 (r 0.66; t-tau 0.59; 0.001). NfL 0.48; By showed be higher than healthy controls (difference 0.63 pg/ml; FTD 0.60 nondegenerative dementias 0.61 an area under curve 0.95 A + A- (95%CI 0.93–0.97). shows excellent results detecting pathology brain level setting AUC 0.95. It is highly specific marker increases progressively along continuum. Using initial cut-offs sensitivities specificities 95 or 97.5% could save 57.4–84.8% LP/PETs accuracies 95–97%. different stages.

Язык: Английский

Процитировано

0
Association of plasma BDNF and MMP-9 levels with mild cognitive impairment: a matched case-control study DOI Creative Commons
Tingyu Zhang, Hang Si,

Jiali Liao

и другие.

Scientific Reports, Год журнала: 2024, Номер 14(1)

Опубликована: Дек. 28, 2024

The prevalence of Alzheimer's disease (AD) is on the rise globally, and everyone who develops AD eventually experiences mild cognitive impairment (MCI) first. Timely intervention at an early stage may mitigate progression. Recent studies indicate that BDNF MMP-9 play a significant role in pathogenesis AD. Therefore, this study aims to ascertain whether there are differences plasma levels between individuals with due those normal cognition, analyze factors influencing impairment.This case-control included 102 controls, matched by age sex. Participants completed series questionnaires, neuropsychological assessments, clinical examinations. Plasma concentrations participants were quantified using ELISA. Subsequently, MCI analyzed univariate multivariate logistic regression. levels, MOCA total scores, scores various domains (including visuospatial executive abilities, abstract thinking, attention, language, naming, delayed memory) control groups showed statistically (p < 0.05). Logistic regression analysis revealed years formal education significantly negatively associated MCI. This indicates protective function.

Язык: Английский

Процитировано

1